This database contains 750 studies, archived under the term: "aged, 80 and over"
Click here to filter this large number of results.
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies
Anderson, Craig,
Teo, Koon,
Gao, Peggy,
Arima, Hisatomi,
Dans, Antonio,
Unger, Thomas,
Commerford, Patrick,
Dyal, Leanne,
Schumacher, Helmut,
Pogue, Janice,
Paolasso, Ernesto,
Holwerda, Nicolaas,
Chazova, Irina,
Binbrek, Azan,
Young, James,
Yusuf, Salim
Background: cardiovascular risk factors are associated with dementia and cognitive decline. We investigated the effects of renin-angiotensin system blockade on cognitive function in patients aged 55 years and older with established atherosclerotic cardiovascular disease or diabetes with end-organ damage in two clinical trials.; Methods: in the main study, ONTARGET, a double-blind, double-dummy, randomised controlled trial, […]
Lipid lowering agents, cognitive decline, and dementia: the three-city study
Ancelin, Marie-Laure,
Carrière, Isabelle,
Barberger-Gateau, Pascale,
Auriacombe, Sophie,
Rouaud, Olivier,
Fourlanos, Spiros,
Berr, Claudine,
Dupuy, Anne-Marie,
Ritchie, Karen
The aim of this prospective cohort study was to evaluate the effects of lipid lowering agent (LLA) intake on cognitive function in 6,830 community-dwelling elderly persons. Cognitive performance (global cognitive functioning, visual memory, verbal fluency, psychomotor speed, and executive function), clinical diagnosis of dementia, and fibrate and statin use, were evaluated at baseline, and 2, […]
Supervised exercise to reduce agitation in severely cognitively impaired persons
Background: Several studies have shown an improvement in depression, activities of daily living, and agitation in cognitively impaired subjects who undergo a long-term exercise program. These studies have not considered the short-term effects of exercise.; Objectives: The purpose of this study was to investigate the short-term effects of a limited, supervised exercise program on agitation, […]
Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer’s disease patients
Albani, Diego,
Martinelli Boneschi, Filippo,
Biella, Gloria,
Giacalone, Giacomo,
Lupoli, Sara,
Clerici, Francesca,
Benussi, Luisa,
Ghidoni, Roberta,
Galimberti, Daniela,
Squitti, Rosanna,
Mariani, Stefania,
Confaloni, Annamaria,
Bruno, Giuseppe,
Mariani, Claudio,
Scarpini, Elio,
Binetti, Giuliano,
Magnani, Giuseppe,
Franceschi, Massimo,
Forloni, Gianluigi
Alzheimer’s disease (AD) is a neurodegenerative disorder often treated with donepezil, an acetylcholinesterase inhibitor. Response to donepezil is variable, probably based on patients’ genetic background in donepezil metabolizing enzymes, including cytochrome 2D6 (CYP2D6). We evaluated the association between clinical response to donepezil and a common variant (rs1080985) of CYP2D6, previously reported to be associated with […]
Normal pressure hydrocephalus or neuroborreliosis?
Background: An 80-year-old woman presented with progressive cognitive decline and with a 6-month history of gait ataxia. Brain MRI depicted enlarged ventricles and periventricular lesions. Clinical improvement after CSF spinal tap test suggested a normal pressure hydrocephalus syndrome. But CSF pleocytosis with activated lymphocytes and plasma cells and intrathecal Borrelia burgdorferi specific antibody production led […]
Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
Aarsland, Dag,
Ballard, Clive,
Walker, Zuzana,
Bostrom, Fredrik,
Alves, Guido,
Kossakowski, Katja,
Leroi, Iracema,
Pozo-Rodriguez, Francisco,
Minthon, Lennart,
Londos, Elisabet
Background: Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are common forms of dementia that substantially affect quality of life. Currently, the only treatment licensed for PDD is rivastigmine, and there are no licensed treatments for DLB. We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine […]